PHASE 2 EFFICACY AND SAFETY OF AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTE (TIL) CELL THERAPY IN COMBINATION WITH PEMBROLIZUMAB IN IMMUNE CHECKPOINT INHIBITOR-NAIVE PATIENTS WITH ADVANCED CANCERS

被引：20

作者：

O'Malley, David ^{[1
]}

Lee, Sylvia ^{[2
]}

Psyrri, Amanda ^{[3
]}

Sukari, Ammar ^{[4
]}

Thomas, Sajeve ^{[5
]}

Wenham, Robert ^{[6
]}

Gogas, Helen ^{[7
]}

Jazaeri, Amir ^{[8
]}

Monk, Bradley ^{[9
]}

Rose, Peter ^{[10
]}

Reuda, Antonio ^{[11
]}

Finckenstein, Friedrich Graf ^{[12
]}

Jagasia, Madan ^{[12
]}

Fiaz, Rana ^{[12
]}

Garelik, Brigid ^{[12
]}

Shi, Wen ^{[12
]}

Desai, Anjali ^{[12
]}

Sulur, Giri ^{[12
]}

Chen, Guang ^{[12
]}

Wu, Xiao ^{[12
]}

Jimeno, Antonio ^{[13
]}

机构：

[1] Ohio State Univ, Columbus, OH 43210 USA

[2] Fred Hutchinson Canc Ctr, Seattle, WA USA

[3] Attikon Univ, Gen Hosp, Athens, Greece

[4] Karmanos Canc Inst, Detroit, MI USA

[5] Orlando Hlth Canc Inst, Orlando, FL USA

[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[7] Natl & Kapodistrian Univ Athen, Athens, Greece

[8] MD Anderson Canc Ctr, Houston, TX USA

[9] US Oncol Network, Arizona Oncol, Phoenix, AZ USA

[10] Cleveland Clin, Columbud, OH USA

[11] Hosp Reg Univ Malag, Malaga, Spain

[12] Iovance Biotherapeut Inc, San Carlos, CA USA

[13] Univ Colorado, Sch Med, Aurora, CO USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷

关键词：

D O I：

10.1136/jitc-2021-SITC2021.492

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

492

引用

页码：A523 / A524

页数：2

共 50 条

[31] Tumor-Infiltrating PD-1hiCD8+-T-Cell Signature as an Effective Biomarker for Immune Checkpoint Inhibitor Therapy Response Across Multiple Cancers
Yang, Zhenyu
Deng, Yulan
Cheng, Jiahan
Wei, Shiyou
Luo, Hao
Liu, Lunxu
FRONTIERS IN ONCOLOGY, 2021, 11
[32] Exploring the safety and efficacy of GT201 as a first-in-class autologous tumor-infiltrating lymphocyte monotherapy in advanced solid tumors.
Han, Zhengxiang
Fang, Weijia
Chen, Kai
Chen, Youguo
Wang, Hongmei
Tang, Juanjuan
Yu, Jing
Ma, Liqing
Liu, Yishan
Lu, Lili
Shen, Derun
Zhai, Xue
Wang, Pin
Liu, Yarong
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[33] Artificial intelligence (AI)-powered spatial tumor-infiltrating lymphocyte (TIL) analysis in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint inhibitor (ICI) treatment
Hong, M.
Kim, C. G.
Hong, M. H.
Koh, Y. W.
Hong, H. J.
Kim, D.
Sim, N. S.
Lee, C. G.
Kim, K. H.
Kim, S.
Oum, C.
Lim, Y.
Song, S.
Ock, C. Y.
Yoon, S. O.
Kim, H. R.
ANNALS OF ONCOLOGY, 2023, 34 : S564 - S564
[34] Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naive Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study
Mascarenhas, John
Rampal, Raajit K.
Grosicki, Sebastian
Chraniuk, Dominik
Abruzzese, Elisabetta
Bose, Prithviraj
Gerds, Aaron
Vannucchi, Alessandro M.
Palandri, Francesca
Lee, Sung-Eun
Gupta, Vikas
Lucchesi, Alessandro
Oh, Stephen T.
Kuykendall, Andrew T.
Patriarca, Andrea
Alvarez-Larran, Alberto
Mesa, Ruben
Kiladjian, Jean-Jacques
Talpaz, Moshe
Lavie, David
Harris, Morgan
Kays, Sarah-Katharina
Jegg, Anna Maria
Wu, Manlei
Brown, Barbara
Harrison, Claire
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S416 - S417
[35] The efficacy and safety of the combination of axitinib and pembrolizumab-activated autologous DC-CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study
Song, Meng-Jia
Pan, Qiu-Zhong
Ding, Ya
Zeng, Jianxiong
Dong, Pei
Zhao, Jing-Jing
Tang, Yan
Li, Jingjing
Zhang, Zhiling
He, Junyi
Yang, Jieying
Huang, Yue
Peng, Ruiqing
Wang, Qi-Jing
Gu, Jia-Mei
He, Jia
Li, Yong-Qiang
Chen, Shi-Ping
Huang, Rongxing
Zhou, Zi-Qi
Yang, Chaopin
Han, Yulong
Chen, Hao
Liu, Heping
Xia, Shangzhou
Wan, Yang
Weng, De-Sheng
Xia, Liming
Zhou, Fang-Jian
Xia, Jian-Chuan
CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2021, 10 (03)
[36] A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma
Chowdhury, Simon
Infante, Jeffery R.
Hawkins, Robert
Voss, Martin H.
Perini, Rodolfo
Arkenau, Tobias
Voskoboynik, Mark
Aimone, Paola
Naeije, Isabelle
Reising, Albert
McDermott, David F.
CLINICAL GENITOURINARY CANCER, 2021, 19 (05) : 434 - 446
[37] A Phase 2 Multicenter Study of Iovance Autologous Tumor Infiltrating Lymphocytes (TIL, LN-145) Cell Therapy in Patients With Metastatic NSCLC
Massarelli, E.
Schoenfeld, A.
Chesney, J.
Hong, Y.
Lammers, P.
Nieva, J.
Wise-Draper, T.
Goldberg, Z.
Cacovean, A.
Yadav, B.
Chen, G.
Jagasia, M.
Finckenstein, F. Graf
Fardis, M.
Sukari, A.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1012 - S1012
[38] Dynamics of circulating cytokines and chemokines during and after tumor-infiltrating lymphocyte cell therapy with lifileucel in advanced melanoma patients
Qi, Rongsu
Sarnaik, Amod
Kirkwood, John M.
Larkin, James
Weber, Jeffrey S.
Blaskovich, Michelle
Kunkalla, Kranthi
Fiaz, Rana
Sulur, Giri
Chou, Jeffrey
Yin, Hequn
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[39] Adoptive Cell Therapy Using Expanded Autologous Tumor-infiltrating Lymphocytes in Metastatic Melanoma Patients: Role of Specific Lymphocyte Subsets
Bernatchez, Chantale
Zhang, Minying
Fox, Patricia S.
Chacon, Jessica Ann
Wu, Cheng-Han
Lizee, Gregory
Mahoney, Sandy L.
Alvarado, Gladys
Mansaray, Rahmatu
Fulbright, Orenthial J.
Toth, Christopher L.
Ramachandran, Renjith
Wardell, Seth
Gonzalez, Audrey M.
Hwu, Patrick
Radvanyi, Laszlo
JOURNAL OF IMMUNOTHERAPY, 2012, 35 (09) : 721 - 721
[40] An Open-Label Phase II Trial of Pembrolizumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Azacitidine as Second-Line Therapy for Advanced Head and Neck Squamous Cell Cancers
Ramani, Vinod K.
Gayen, Srimonta
Naik, Radheshyam
HEALTH SCIENCE REPORTS, 2025, 8 (01)

← 1 2 3 4 5 →